N-[4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-benzyl]-hydroxylamine | 166262-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: N-[4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-benzyl]-hydroxylamine
• 英文别名: N-[[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]hydroxylamine
• CAS: 166262-35-7
• 化学式: C₁₇H₁₉N₃O₃
• 分子量: 313.356
• InChiKey: CBSXCYBSEPKHKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  70.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-benzyl]-hydroxylamine 在 乙酸酐 作用下， 以 四氢呋喃 为溶剂， 以77%的产率得到N-[4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-benzyl]-N-hydroxy-acetamide
  参考文献：
  名称：

  Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and

  摘要：

  本发明涉及抑制花生四烯酸代谢中脂氧合酶的化合物，从而抑制与炎症过程和支气管收缩有关的白三烯的形成，并抑制与动脉粥样硬化斑块形成有关的低密度脂蛋白的氧化。本发明中有用的化合物由以下式子表示：##STR1## 其中：R.sup.2是氢，卤素或C.sub.1-C.sub.6烷基; Y为O或S; R.sup.5是氢或甲基; R.sup.6是--NH.sub.2，--CH.sub.3或--OCH.sub.3; R.sup.1是##STR2## 其中R.sup.7，R.sup.8和R.sup.10独立地是卤素，三氟甲基，烷基，烷氧基，甲磺酰基或三氟甲磺酰基; R.sup.9是氢或甲基; Z为O或S，或其药学上可接受的盐。当R.sup.3为H且R.sup.6为--NH.sub.2时，上述式子中R.sup.1不是##STR3## 的化合物是新的。

  公开号：

  US05428048A1
• 作为产物：
  描述：

  4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]-benzaldehyde 在 盐酸 、 盐酸羟胺 、 sodium acetate 、 methyl orange 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 生成 N-[4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-benzyl]-hydroxylamine
  参考文献：
  名称：

  Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

  摘要：

  A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg(-1) oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg(-1) oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg(-1) oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg(-1) oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg(-1) oral dose. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)01191-0

文献信息

• Aryl-n-hydroxyureas as inhbitors of 5-lipoxygenase and
  申请人：American Home Products Corporation

  公开号：US05541205A1

  公开（公告）日：1996-07-30

  This invention relates to compounds which inhibit lipoxygenase in the metabolism of arachidonic acid and thus inhibits formation of leukotrienes which are implicated in inflammatory processes and bronchoconstriction and inhibits the oxidation of LDL which is implicated in formation of atherosclerotic plaque. The compounds useful in this invention are represented by the formula: ##STR1## wherein: R.sup.2 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; Y of O or S;R.sup.5 is hydrogen or methyl R.sup.6 is --NH.sub.2, --CH.sub.3 or --OCH.sub.3 ; and R.sup.1 is ##STR2## wherein R.sup.7, R.sup.8 and R.sup.10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifluoromethanesulfonyl; R.sup.9 is hydrogen or methyl; and Z is O or S, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种抑制花生四烯酸代谢中脂氧合酶的化合物，从而抑制与炎症过程和支气管收缩有关的白三烯的形成，并抑制与动脉粥样硬化斑块形成有关的低密度脂蛋白的氧化。本发明中有用的化合物由以下公式表示： 其中：R.sup.2为氢，卤素或C.sub.1-C.sub.6烷基；Y为O或S；R.sup.5为氢或甲基；R.sup.6为--NH.sub.2，--CH.sub.3或--OCH.sub.3；R.sup.1为以下公式： 其中，R.sup.7，R.sup.8和R.sup.10独立地为卤素，三氟甲基，烷基，烷氧基，甲烷磺酰基或三氟甲磺酰基；R.sup.9为氢或甲基；Z为O或S，或其药学上可接受的盐。
• US5428048A
  申请人：——

  公开号：US5428048A

  公开（公告）日：1995-06-27
• US5541205A
  申请人：——

  公开号：US5541205A

  公开（公告）日：1996-07-30
• Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones
  作者：M Malamas

  DOI：10.1016/s0223-5234(00)01191-0

  日期：2001.1

  A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg(-1) oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg(-1) oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg(-1) oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg(-1) oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg(-1) oral dose. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
• Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and
  申请人：American Home Products Corporation

  公开号：US05428048A1

  公开（公告）日：1995-06-27

  This invention relates to compounds which inhibit lipoxygenase in the metabolism of arachidonic acid and thus inhibits formation of leukotrienes which are implicated in inflammatory processes and bronchoconstriction and inhibits the oxidation of LDL which is implicated in formation of atherosclerotic plaque. The compounds useful in this invention are represented by the formula: ##STR1## wherein: R.sup.2 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; Y of O or S; R.sup.5 is hydrogen or methyl R.sup.6 is --NH.sub.2, --CH.sub.3 or --OCH.sub.3 ; and R.sup.1 is ##STR2## wherein R.sup.7, R.sup.8 and R.sup.10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifiuoromethanesulfonyl; R.sup.9 is hydrogen or methyl; and Z is O or S, or a pharmaceutically acceptable salt thereof. Compounds of the above formula where R.sup.1 is not ##STR3## when R.sup.3 is H and R.sup.6 is --NH.sub.2 are novel.

  本发明涉及抑制花生四烯酸代谢中脂氧合酶的化合物，从而抑制与炎症过程和支气管收缩有关的白三烯的形成，并抑制与动脉粥样硬化斑块形成有关的低密度脂蛋白的氧化。本发明中有用的化合物由以下式子表示：##STR1## 其中：R.sup.2是氢，卤素或C.sub.1-C.sub.6烷基; Y为O或S; R.sup.5是氢或甲基; R.sup.6是--NH.sub.2，--CH.sub.3或--OCH.sub.3; R.sup.1是##STR2## 其中R.sup.7，R.sup.8和R.sup.10独立地是卤素，三氟甲基，烷基，烷氧基，甲磺酰基或三氟甲磺酰基; R.sup.9是氢或甲基; Z为O或S，或其药学上可接受的盐。当R.sup.3为H且R.sup.6为--NH.sub.2时，上述式子中R.sup.1不是##STR3## 的化合物是新的。